Children’s Oncology Group Chemotherapy Standardization Task Force
Abstract
An analysis of dose modifications for infants in 29 Children’s Oncology Group protocols across 10 cancer types revealed 11 sets of criteria defining the infant population using age, weight, body surface area (BSA), or a combination of these parameters and eight dose modification methods. A new method of dosing anticancer drugs in infants was developed based on the rationale that prior modifications were implemented to reduce toxicity, which is not cancer-specific. The new method uses BSA dose banding in dosing tables for infants and children with a BSA < 0.6 m2 and gradually transitions from body weight based to BSA-based dosing.
About the Authors
F. M. Balis
The Children’s Hospital of Philadelphia
United States
United States
Department of Pediatrics
Philadelphia, Pennsylvania
R. B. Womer
The Children’s Hospital of Philadelphia
United States
United States
Department of Pediatrics
Philadelphia, Pennsylvania
S. Berg
Texas Children’s Cancer Center
United States
United States
Department of Pediatrics
Houston, Texas
N. Winick
University of Texas Southwestern
United States
United States
Department of Pediatrics
Dallas, Texas
P. C. Adamson
The Children’s Hospital of Philadelphia
United States
United States
Department of Pediatrics
Philadelphia, Pennsylvania
E. Fox
The Children’s Hospital of Philadelphia
United States
United States
Department of Pediatrics
Philadelphia, Pennsylvania
References
1. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996;14(9):2590–11.
2. Goldsmith M.A., Slavik M., Carter S.K. Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res 1975;35(5):1354–64.
3. Pinkel D. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 1958;18(7):853–6.
4. Baker S.D., Verweij J., Rowinsky E.K. et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991– 2001. J Natl Cancer Inst 2002;94(24):1883–8.
5. Ratain M.J. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol 1998;16(7):2297–8.
6. Felici A., Verweij J., Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer 2002;38(13):1677–84.
7. Chatelut E., Puisset F. The scientific basis of body surface area-based dosing. Clin Pharmacol Ther 2014;95(4):359–61.
8. Chatelut E., White-Koning M.L., Mathijssen R.H. et al. Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. Br J Cancer 2012;107(7):1100–6.
9. Coppoletta J.M., Wolbach S.B. Body length and organ weights of infants and children. Am J Pathol 1932;9:55–70.
10. Bagatell R., Herzog C.E., Trippett T.M. et al. Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors. Clin Cancer Res 2011;17(3):611–9.
11. Fox E., Maris J.M., Cohn S.L. et al. Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. Cancer Chemother Pharmacol 2010;66(4):737–43.
12. Kanamori M., Takahashi H., Echizen H. Developmental changes in the liver weight-and body weight-normalized clearance of theophylline, phenytoin and cyclosporine in children. Int J Clin Pharmacol Ther 2002;40(11):485–92.
13. Morgan E., Baum E., Breslow N., Takashima J., D’Angio G. Chemotherapy related toxicity in infants treated according to the Second National Wilms’ Tumor Study. J Clin Oncol 1988;6(1):51–5.
14. Woods W.G., O’Leary M., Nesbit M.E. Life-threatening neuropathy and hepatotoxicity in infants during induction therapy for acute lymphoblastic leukemia. J Pediatr 1981;98(4):642–5.
15. Aperia A., Broberger O., Thodenius K., Zetterstrom R. Development of renal control of salt and fluid homeostasis during the first year of life. Acta Paediatr 1975;64(3):393–8.
16. Guignard J.P., Torrado A., Da Cunha O., Gautier E. Glomerular filtration rate in the first three weeks of life. J Pediatr 1975;87(2):268–72.
17. Kearns G.L. Pharmacogenetics and development: are infants and children at increased risk for adverse outcomes? Curr Opin Pediatr 1995;7(2):220–33.
18. Cresteil T. Onset of xenobiotic metabolism in children: toxicological implications. Food Addit Contam 1998;15(Suppl):45–51.
19. Upreti V.V., Wahlstrom J.L. Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling. J Clin Pharmacol 2016;56:266–83.
20. Langholz B., Skolnik J.M., Barrett J.S. et al. Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children’s Oncology Group. Pediatr Blood Cancer 2011;57(2):252–7.
Review
For citations:
Balis F.M., Womer R.B., Berg S., Winick N., Adamson P.C., Fox E. Children’s Oncology Group Chemotherapy Standardization Task Force. Russian Journal of Pediatric Hematology and Oncology. 2018;5(1):11-16. (In Russ.)
Views:
597
Email this article 